⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HRTX News
Heron Therapeutics, Inc.
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
globenewswire.com
HRTX
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
globenewswire.com
HRTX
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
globenewswire.com
HRTX
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
globenewswire.com
HRTX
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
globenewswire.com
HRTX